CAR-T in blood cancers
Chimeric antigen receptor T-cell therapy in lymphoma, myeloma and leukaemia.
Key point
CAR T-cell therapy has emerged as an effective option for refractory or progressive mantle cell lymphoma after prior covalent BTK inhibitor treatment.
From: B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology (J Natl Compr Canc Netw, 2026 Sep) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 171, 186, 191, 226, 233.
New guidelines and consensus this year
- [Guidelines for the diagnosis and management of multiple myeloma in China (2026 revision)]Zhonghua Nei Ke Za Zhi2026 Oct 1
- The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guidelineBr J Haematol2026 Oct
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0J Immunother Cancer2026 Sep 21
- B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyJ Natl Compr Canc Netw2026 Sep
- Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committeeBone Marrow Transplant2026 Sep
All papers from the last 12 months
1,955 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Targeting CARM1 impairs DNA damage repair and attenuates B-cell acute lymphoblastic leukemia progressionBiochim Biophys Acta Mol Basis Dis2027 JanPMID 42669369
- Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemiaOncoimmunology2026 Dec 31PMID 42750591
- CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectivelyHematology2026 Dec 31PMID 42629973
- CAR T therapy in adult DLBCL patients in Slovenia: Evaluation of predictive scores for outcomes and adverse eventsHum Vaccin Immunother2026 Dec 31PMID 41614438
- Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025Hum Vaccin Immunother2026 DecPMID 42623170
- Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal - A modeling approachJ Med Econ2026 DecPMID 42596901
- Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypesHum Vaccin Immunother2026 DecPMID 42532836Review
- Research trends and hotspots of CAR-T cell therapy for acute lymphoblastic leukemia: A bibliometric analysisHum Vaccin Immunother2026 DecPMID 42473738
- Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulationAnn Med2026 DecPMID 41800605Review
- Time to access matters: patient gains from faster CAR T-cell reimbursement in EuropeJ Med Econ2026 DecPMID 41705912
More hematology trends
All specialties →Bispecific antibodies in myeloma
Teclistamab, elranatamab and talquetamab in multiple myeloma.
Measurable residual disease
Detecting residual disease after treatment of blood cancers.
Gene therapy for sickle cell and thalassaemia
CRISPR-based and lentiviral gene therapies for haemoglobin disorders.
Immune thrombocytopenia
ITP and its newer treatments.
Key point: Adult ITP care incorporates newer thrombopoietin receptor agonists and small molecule kinase inhibitors, emphasizing thrombotic risk and quality of life.
DOACs in cancer-associated thrombosis
Direct oral anticoagulants for venous thromboembolism in people with cancer.
Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("CAR-T"[tiab] OR "CAR T"[tiab] OR "chimeric antigen receptor"[tiab]) AND (lymphoma[tiab] OR myeloma[tiab] OR leukemia[tiab] OR leukaemia[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.